Edwards, St. Jude Transcatheter Valve Programs Mark Progress
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences and St. Jude Medical each marked notable milestones in the closely watched transcatheter aortic valve space last week.
You may also be interested in...
Regulatory News In Brief
Human factors guidance
Regulatory News In Brief
Human factors guidance
Getting Set For Sapien: With Data In, Discussion Moves To Adoption Dynamics
With all the major clinical data from Edwards Lifesciences' closely watched PARTNER trial now out in the open, there is little doubt among clinicians and industry analysts that transcatheter aortic heart valve replacements will be a U.S. commercial reality in the near term.